ライフサイエンスコーパス: courage

1 s essay, the trailblazers whose intellectual courage and persistence has brought us to this happy pos

2 edures was suboptimal; and 3) the results of COURAGE are not applicable to current clinical practice.

3 We obtained data from the COURAGE (Clinical Outcomes Utilizing Revascularization a

4 However, the more recent COURAGE (Clinical Outcomes Utilizing Revascularization a

5 nfarction (MI) in stable CAD patients in the COURAGE (Clinical Outcomes Utilizing Revascularization a

6 er describes the medical therapy used in the COURAGE (Clinical Outcomes Utilizing Revascularization a

7 The COURAGE (Clinical Outcomes Utilizing Revascularization a

8 The COURAGE (Clinical Outcomes Utilizing Revascularization a

9 The COURAGE (Clinical Outcomes Utilizing Revascularization a

10 with optimal risk factor levels based on the COURAGE (Clinical Outcomes Utilizing Revascularization a

11 Qualities of confidence, compassion, courage, commitment, communication, courtesy, and especi

12 Courage, confidence, creativity, compassion, charisma, c

13 trol, and smoking cessation, only 18% of the COURAGE diabetes subgroup, 23% of BARI 2D patients, and

14 d with baseline increased from 55% to 77% in COURAGE, from 59% to 75% in BARI 2D, and from 34% to 42%

15 d to each of these points, and conclude that COURAGE indeed provides relevant new information to assi

16 cularization and Aggressive Drug Evaluation [COURAGE]; NCT00007657).

17 cularization and Aggressive Drug Evaluation (COURAGE) nuclear substudy compared the effectiveness of

18 is supplement is dedicated to the memory and courage of Hank Schueler, who fought valiantly against t

19 Among COURAGE patients assigned to OMT alone, patients' angina

20 In COURAGE patients who underwent serial MPS, adding PCI to

21 Of the 2287 COURAGE patients, 314 were enrolled in this substudy of

22 cularization and Aggressive Drug Evaluation (COURAGE) study, which provided optimal medical therapy (

23 ill take commitment, advocacy, and political courage to advance the action agenda.

24 s with the highest levels of utilization pre-COURAGE trial (35% decline in the highest tertile versus

25 ients (44.7%; 95% CI, 44.5%-44.8%) after the COURAGE trial (P < .001).

26 e (2006) and after (2008) publication of the COURAGE trial and compared those with contemporaneous ch

27 ents (43.5%; 95% CI, 43.2%-43.7%) before the COURAGE trial and in 131,188 patients (44.7%; 95% CI, 44

28 intensively to both treatment groups in the COURAGE trial by nurse case managers with treatment prot

29 An in-depth analysis of the COURAGE trial design and execution is provided.

30 Optimal medical therapy in the COURAGE trial provides an effective model for secondary

31 The COURAGE trial tested multiple lifestyle and pharmacologi

32 discharge following PCI before and after the COURAGE trial was 63.5% (95% CI, 63.3%-63.7%) and 66.0%

33 before [37.1%] and 293,795 after [62.9%] the COURAGE trial) meeting study criteria, OMT was used in 2

34 After the publication of the COURAGE trial, PCI volume for SIHD declined by 25% (P<0.

35 In the COURAGE trial, the addition of percutaneous coronary int

36 Among stable CAD patients in the COURAGE trial, the presence of MetS identified increased

37 in PCI for SIHD after the publication of the COURAGE trial.

38 is in 2,193 men and women with SIHD from the COURAGE trial.

39 CI for SIHD preceding the publication of the COURAGE trial.

40 rge, before and after the publication of the COURAGE trial.

41 ctice or whether its use increased after the COURAGE trial.

42 e practice patterns after publication of the COURAGE trial.

43 tes OMT, based largely on the results of the COURAGE trial.

44 CAD meeting 7 risk factor goals based on the COURAGE trial: 1) aspirin use; 2) systolic blood pressur

45 cularization and Aggressive Drug Evaluation (COURAGE) trial reignited the controversy of the benefit

46 cularization and Aggressive Drug Evaluation (COURAGE) trial, some patients with stable ischemic heart

47 cularization and Aggressive Drug Evaluation (COURAGE) trial, which will be the largest of the studies

48 cularization and Aggressive Drug Evaluation (COURAGE) trial.

49 COURAGE was not designed to evaluate changes in the freq

50 Generating the energy, insight, and courage we need to get to "total quality" may require th